Login to Your Account



Other News To Note


Tuesday, October 9, 2012

• Cellerant Therapeutics Inc., of San Carlos, Calif., said it was awarded a Small Business Innovation Research Phase I contract and a Phase II option from the National Cancer Institute valued up to about $1.7 billion.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription